Real-World Experience of the Comparative Effectiveness and Safety of Combination Therapy with Remdesivir and Monoclonal Antibodies versus Remdesivir Alone for Patients with Mild-to-Moderate COVID-19 and Immunosuppression: A Retrospective Single-Center Study in Aichi, Japan.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101509722 Publication Model: Electronic Cited Medium: Internet ISSN: 1999-4915 (Electronic) Linking ISSN: 19994915 NLM ISO Abbreviation: Viruses Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI

Antibodies, Monoclonal*/adverse effects ; COVID-19*; Humans ; Japan ; COVID-19 Drug Treatment ; Retrospective Studies ; Immunosuppression Therapy

The coronavirus disease (COVID-19) pandemic continues to threaten global public health. Remdesivir and monoclonal antibodies have shown promise for COVID-19 treatment of patients who are immunocompromised, including those with cancer, transplant recipients, and those with autoimmune disorder. However, the effectiveness and safety of this combination therapy for patients who are immunosuppressed remain unclear. We compared the efficacy and safety of combination therapy and remdesivir monotherapy for patients with mild-to-moderate COVID-19 who were immunosuppressed. Eighty-six patients treated in July 2021-March 2023 were analyzed. The combination therapy group (CTG) showed a statistically significant reduction in viral load compared with the monotherapy group (MTG) ( p < 0.01). Patients in the CTG also experienced earlier resolution of fever than those in the MTG ( p = 0.02), although this difference was not significant in the multivariate analysis ( p = 0.21). Additionally, the CTG had significantly higher discharge rates on days 7, 14, and 28 than the MTG ( p < 0.01, p < 0.01, and p = 0.04, respectively). No serious adverse events were observed with combination therapy. These findings suggest that combination therapy may improve the clinical outcomes of immunosuppressed COVID-19 patients by reducing the viral load and hastening recovery. Further studies are required to fully understand the benefits of this combination therapy for immunocompromised COVID-19 patients.

Open Forum Infect Dis. 2022 May 26;9(6):ofac064. (PMID: 35663288)
Lancet. 2022 Feb 12;399(10325):665-676. (PMID: 35151397)
J Infect Dis. 2020 Sep 1;222(7):1103-1107. (PMID: 32702095)
Infect Dis Ther. 2020 Sep;9(3):573-586. (PMID: 32725536)
Nat Rev Immunol. 2021 Jun;21(6):382-393. (PMID: 33875867)
Heliyon. 2023 Feb;9(2):e13126. (PMID: 36713627)
MMWR Morb Mortal Wkly Rep. 2022 Jul 08;71(27):878-884. (PMID: 35797216)
Clin Microbiol Infect. 2022 Feb;28(2):163-177. (PMID: 35020589)
Nat Commun. 2020 Dec 14;11(1):6385. (PMID: 33318491)
J Pharm Pract. 2023 Apr;36(2):407-417. (PMID: 34597525)
Clin Chest Med. 2023 Jun;44(2):395-406. (PMID: 37085228)
N Engl J Med. 2021 Jan 21;384(3):229-237. (PMID: 33113295)
Antibiotics (Basel). 2022 Jan 25;11(2):. (PMID: 35203759)
Br J Haematol. 2020 Jul;190(2):185-188. (PMID: 32557623)
Lancet. 2020 Mar 28;395(10229):1054-1062. (PMID: 32171076)
Virulence. 2022 Dec;13(1):1242-1251. (PMID: 35891618)
Lancet Microbe. 2022 May;3(5):e325-e326. (PMID: 35309711)
ACS Cent Sci. 2020 May 27;6(5):672-683. (PMID: 32483554)
Viruses. 2023 Aug 17;15(8):. (PMID: 37632099)
Nat Rev Rheumatol. 2022 Apr;18(4):191-204. (PMID: 35217850)
Intern Emerg Med. 2023 Aug;18(5):1573-1581. (PMID: 36449260)
Clin Infect Dis. 2023 Feb 8;76(3):e172-e178. (PMID: 35869843)
Immun Inflamm Dis. 2023 Apr;11(4):e806. (PMID: 37102662)
Front Immunol. 2023 Jan 26;14:1125246. (PMID: 36776881)
N Engl J Med. 2022 Jan 27;386(4):305-315. (PMID: 34937145)
Cell. 2020 Dec 23;183(7):1901-1912.e9. (PMID: 33248470)
JAMA Oncol. 2022 Jan 1;8(1):114-122. (PMID: 34817562)
N Engl J Med. 2021 Nov 18;385(21):1941-1950. (PMID: 34706189)
N Engl J Med. 2021 Jan 21;384(3):238-251. (PMID: 33332778)
N Engl J Med. 2021 Aug 5;385(6):562-566. (PMID: 34347959)
Intern Med. 2022 Dec 15;61(24):3703-3708. (PMID: 36171121)
Nat Rev Microbiol. 2021 Mar;19(3):141-154. (PMID: 33024307)
Front Med (Lausanne). 2023 Jan 09;9:1062450. (PMID: 36698815)
Clin Infect Dis. 2021 May 4;72(9):e206-e214. (PMID: 32674114)
Cancer Cell. 2022 Apr 11;40(4):343-345. (PMID: 35219358)
Am J Hematol. 2022 Aug;97(8):E312-E317. (PMID: 35702878)
Vaccines (Basel). 2023 Jan 17;11(2):. (PMID: 36851078)
Expert Opin Biol Ther. 2020 Sep;20(9):1033-1046. (PMID: 32744917)
Ann Hematol. 2022 Oct;101(10):2337-2345. (PMID: 35836007)
N Engl J Med. 2020 Nov 5;383(19):1813-1826. (PMID: 32445440)
J Clin Immunol. 2023 Aug;43(6):1083-1092. (PMID: 37148422)
Viruses. 2021 Jul 27;13(8):. (PMID: 34452325)
N Engl J Med. 2020 Dec 3;383(23):2291-2293. (PMID: 33176080)
MMWR Morb Mortal Wkly Rep. 2020 Jun 19;69(24):759-765. (PMID: 32555134)

Keywords: COVID-19; combination; immunocompromised; monoclonal antibodies; remdesivir

0 (Antibodies, Monoclonal)
3QKI37EEHE (remdesivir)

Date Created: 20230928 Date Completed: 20230929 Latest Revision: 20231004

20250114

PMC10538070

10.3390/v15091952

37766358